PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints
Prasinezumab continues to be well tolerated and no new safety signals w… [+6910 chars]
Lifestyle Natural Medicines
Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease
Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease
